A common chromosomal translocation in acute myeloid leukemia (AML) involves the AML1 (acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBFa), and PEBP2aB) gene on chromosome 21 and the ETO (eight-twenty one, also called MTG8) gene on chromosome 8. This translocation generates an AML1-ETO fusion protein. t(8;21) is associated with 12% of de novo AML cases and up to 40% in the AML subtype M2 of the French-American-British classification. Furthermore, it is also reported in a small portion of M0, M1, and M4 AML samples. Despite numerous studies on the function of AML1-ETO, the precise mechanism by which the fusion protein is involved in leukemia development is still not fully understood. In this review, we will discuss structural aspects of the fusion protein and the accumulated knowledge from in vitro analyses on AML1-ETO functions, and outline putative mechanisms of its leukemogenic potential.
The 8;21 translocation with breaks at 8q22 and 21q22.3 was first reported by Dr Janet Rowley in 1973 during the analysis of a leukemia patient sample (Rowley, 1973) . Two genes (AML1 and ETO) located at these breakpoints were finally identified in the early 1990s by several groups (Gao et al., 1991; Miyoshi et al., 1991; Erickson et al., 1992 Erickson et al., , 1994 Nisson et al., 1992; Shimizu et al., 1992) . As shown in Figure 1 , the classical recognized organization of the AML1 gene on chromosome 21 consists of nine exons and produces at least three proteins (Miyoshi et al., 1995) . Further fine mapping revealed that AML1 gene locus spans 260 kb and there are several additional potential exons (Levanon et al., 2001) . The expression of AML1 is regulated by two independent promoters and alternative splicing (Miyoshi et al., 1995; Levanon et al., 1996 Levanon et al., , 2001 ). The ETO gene on chromosome 8 consists of 13 exons distributed over at least 87 kb ( Figure 1 ) and also has alternative spliced forms (Wolford and Prochazka, 1998) . The breakpoints within the AML1 locus are clustered in the classically recognized intron 5, with three breakpoint cluster regions (BCR) . On the other hand, the breakpoints are clustered in two introns of ETO (Tighe et al., 1993; Tighe and Calabi, 1995) , with one BCR in intron 1a (Tighe and Calabi, 1995) and three BCRs in intron 1b (Xiao et al., 2001; Zhang et al., 2002) . These breakpoints create the same chimeric transcript of AML1-ETO due to the lack of any splice acceptor site in exon 1b of ETO (Kozu et al., 1993; de Greef et al., 1995; Xiao et al., 2001) . Interestingly, the clusters of AML1 and ETO breakpoints are associated with topoisomerase II DNA cleavage and DNase I hypersensitive sites . Such phenomenon is also present in translocation breakpoints of other genes of leukemia-associated translocations (Felix, 1998) . In addition, complex translocations involving chromosomes 8 and 21 also express the same AML1-ETO fusion gene, suggesting that the breakpoint regions are the same (Kozu et al., 1993; de Greef et al., 1995) . Overall, no translocation has been identified between AML1 and ETO that occurs outside these intron boundaries that produce the AML1-ETO fusion protein.
AML1 is a member of the RUNX (PEBP2a, core binding factor protein (CBFa), AML) family, which includes AML1 (RUNX1, PEBP2aB, CBFa2), AML2 (RUNX3, PEBP2aC, CBFa3), and AML3 (RUNX2, PEBP2aA, CBFa1). All RUNX proteins contain a runt homology DNA binding domain, which is highly homologous to the Drosophila Runt protein. Runt is involved in segmentation and sexual determination (Kania et al., 1990; Duffy and Gergen, 1991) . Besides the DNA binding runt homology domain, AML1 also contains a transactivation domain Kurokawa et al., 1996) , nuclear matrix attachment signal (NMTS) (Zeng et al., 1998) , and two inhibitory domains (Imai et al., 1998; Kanno et al., 1998; Levanon et al., 1998) . Furthermore, AML1 forms a heterodimer with the CBFb facilitating efficient DNA binding (Ogawa et al., 1993) . In the 8;21 translocation, AML1 contributes the N-terminal region, including runt homology domain, thus making AML1-ETO able to bind AML1 target gene promoters (Figure 2) .
The ETO protein belongs to the ETO family, which includes ETO (MTG8), ETO2 (MTG16, MTG8-related 2 (MTGR2)), and MTGR1 (Calabi and Cilli, 1998; Kitabayashi et al., 1998) . All three members of this family have four evolutionarily conserved Nervy homology domains termed Nervy homology regions (NHR) 1-4 based on their homology to the Drosophila protein Nervy, which is involved in neuronal development during segmentation of Drosophila embryos (Feinstein et al., 1995) . NHR1 has homology with the Drosophila TATA-box-associated factor 110 (TAF110) and other TAFs (Erickson et al., 1994) . The NHR2 domain contains a hydrophobic amino-acid (a.a.) heptad repeat and is required for homo-and heterodimerization between the ETO family members (Gelmetti et al., 1998; Kitabayashi et al., 1998; Zhang et al., 2001) . NHR3 contains a predicted coiled-coil structure (Minucci et al., 2000) . NHR4 is a myeloidNervy-DEAF1 homology domain with two predicted zinc-finger motifs (CxxCCxxC and a CxxCHxxC) (Erickson et al., 1994; Gross and McGinnis, 1996) . These zinc-finger motifs of ETO are involved in proteinprotein interaction, but not protein-DNA interaction. AML1-ETO contains almost the entire ETO protein (Figure 2 ).
Protein-protein interactions
Since AML1-ETO contains the N-terminal portion of AML1 including the intact runt homology domain, it may interact with other transcription regulators known to bind to this region of AML1 (Figure 2 ). The first and the best known AML1 binding protein is its heterodimer partner CBFb (also called PEBP2b) that promotes efficient DNA binding of AML1 and is essential for the full activity of AML1 transcriptional activation (Ogawa et al., 1993; Wang et al., 1993 Wang et al., , 1996a Kanno et al., 1998) . Most protein-protein interactions involving the runt homology domain (RHD) of AML1 were identified due to the proximity of the AML1 binding site to the DNA binding sites of these transcription factors, including Ets-1, LEF-1, C/EBPa, PU.1, MEF, Pax5, and GATA1 Petrovick et al., 1998; Kim et al., 1999; Libermann et al., 1999; Mao et al., 1999; Goetz et al., 2000; Gu et al., 2000; Elagib et al., 2003; Li et al., 2004) . For example, AML1 binding sites overlap with Ets-1 sites and are close to LEF-1 sites in enhancers of several T-cell receptors (Hsiang et al., 1993; Wotton et al., 1994; Giese et al., 1995; Mayall et al., 1997) . AML1 associates with these adjacent transcription factors and enhances their interaction to DNA (Sun et al., 1995) . Furthermore, C/EBPa and PU.1 bind to the adjacent sites of AML1 consensus sequence in human M-CSF receptor promoter. They interact with the RHD of AML1 with differing potentials in the synergistic activation of the M-CSF receptor Petrovick et al., 1998) .
The first ETO-interacting protein identified was its family member MTGR1 (Kitabayashi et al., 1998) . MTGR1 shares 61% identity with ETO and also contains four Nervy homology domains. The NHR2 domain plays a critical role in the interaction between ETO and MTGR1. Another ETO family member, ETO2, also interacts with ETO via NHR2 domain (Davis et al., 1999) . Using ETO as bait or silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT) as bait in two independent yeast twohybrid protein interaction studies and based on the educated guess, three groups reported almost simultaneously that nuclear receptor corepressor (NCoR) and SMRT bind to the NHR4 zinc-finger domain of ETO (Gelmetti et al., 1998; Lutterbach et al., 1998b; Wang et al., 1998) . NCoR and SMRT are nuclear hormone corepressors, which are released from nuclear hormone receptors upon ligand binding, allowing transcriptional activation (Shibata et al., 1997; Chen and Li, 1998) . These corepressor proteins are known to associate with other proteins involved in transcriptional repression, such as mSin3a and the histone deacetylase (HDAC) family (Shibata et al., 1997; Chen and Li, 1998) . Therefore, via NCoR and SMRT, AML1-ETO can assemble a transcription repressor complex on AML1 target regulatory sequence and negatively regulate gene expression. It has been demonstrated that the NHR4 region plays a critical role in such negative regulation of the activity of AML1 target promoters (Gelmetti et al., 1998; Lutterbach et al., 1998a, b; Wang et al., 1998) . Further analysis revealed that NCoR, mSin3a, and different HDAC family members can interact with various regions of ETO and also negatively regulate AML1 targets (Amann et al., 2001; Hildebrand et al., 2001) (Figure 2 ). In addition, the dimerization of ETO or AML1-ETO with AML1-ETO also plays an important role in the regulation of AML1 target promoter activities (Minucci et al., 2000; Zhang et al., 2001) . Atrophin-1 is a protein widely expressed and involved in the neurodegenerative disease dentate-rubral and pallidoluysian atrophy. A yeast two-hybrid study for identifying associated proteins of atrophin-1 showed that five of the seven positive clones were ETO and one clone was ETO2 (Wood et al., 2000) . Furthermore, atrophin-1 is colocalized with ETO in the nucleus, repressing gene expression (Wood et al., 2000) . Using yeast twohybrid and biochemical copurification approaches, Kozu's group reported that the N-terminal region of ETO interacts with chaperon heat-shock protein (HSP90) and the NHR3 domain of ETO bind to the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RIIa) (Komori et al., 1999; Fukuyama et al., 2001) . Other proteins that interact with ETO were found by investigating the possibility of interaction due to the presence of both proteins in hematopoietic cells, such as PLZF (Melnick et al., 2000b) , Gfi-1 (McGhee et al., 2003) , and Bcl-6 (Chevallier et al., 2004) . All these interactions highlight a mechanism for ETO function as a corepressor in the repressive activity of transcription factors. Thus the dominant-negative effect of AML1-ETO on AML1 and other transcriptional regulators, discussed below, could be exacerbated through such interactions and dimerizations.
Accumulating data indicate that NMTS of various transcription factors may influence the specific localization and local concentration of transcription factors and provide additional specificities for these factors in gene expression (Davie, 1997) . In addition, many of the corepressor proteins that interact with AML1-ETO are associated with such nuclear matrix foci (Davie et al., 1999; Wood et al., 2000) . AML1 contains an NMTS on the C-terminal side of runt homology domain, which is not included in the AML1-ETO fusion protein. Interestingly, ETO contains one nuclear localization signal (a.a. 241-280) and two NMTS (a.a. 197-387 and a.a. 438-552) (Odaka et al., 2000; Barseguian et al., 2002) . It has been reported that AML1 and ETO do not share the same subnuclear locations and that AML1-ETO is colocalized with ETO in specific nuclear foci (McNeil et al., 1999; Odaka et al., 2000) . Such relocalization of the AML1 DNA binding activity by AML1-ETO may therefore contribute to the deregulation of AML1 target genes.
Multiple transcriptional functions of AML1-ETO
A main functional characteristic of AML1-ETO is its ability to bind DNA containing AML1 binding sites (TG T / C GGT) (Meyers et al., 1993) . Many transient transfection reporter gene studies looking at the transcriptional aspect of AML1-ETO suggest that AML1-ETO negatively regulate AML1 target genes. Such targets include MDR-1, GM-CSF receptor, IL-3, c-fos, TCRb enhancer, immunoglobulin a promoter, and most recently identified p14 ARF (Table 1) . The negative regulatory effect of AML1-ETO was first reported from the analysis of AML1 transactivation of TCRb enhancer . This inhibition was attributed to the ETO portion of the protein and a very low amount of AML1-ETO was required to inhibit AML1 transactivation. In this early report, AML1-ETO alone did not show any negative effect on TCRb enhancer activity. A similar negative regulation of AML1-ETO on AML1 transactivation of the GM-CSF promoter was also reported (Frank et al., 1995) . Here, the repressor activity of AML1-ETO in the absence of AML1 cotransfection was detected. Recently, the inhibition of the promoter activity of cell cycle protein p14 ARF by AML1-ETO was reported, in which the inhibition was dependent on the RHD and NHR2-4 region of AML1-ETO (Linggi et al., 2002) . Interestingly, a mutant of AML1-ETO, AML1-ETOD395 without ETO NHR2-4 showed the block of c-fos promoter induction in an AML1 binding site-dependent manner in reporter assays. Furthermore, the induction of endogenous c-fos mRNA expression in the response of G-CSF stimulation was also blocked in 32Dcl3 granulocytic progenitor cell expressing AML1-ETOD395 (Hwang et al., 1999) .
Besides the negative effect of AML1-ETO on gene expression, AML1-ETO was also reported as a positive regulator, which is either dependent on or independent of AML1 protein and AML1 DNA binding sites. As shown in Table 1 , the proximal promoter of human M-CSF receptor (c-fms) contains an AML1 binding site (Zhang et al., 1994) . AML1 expression significantly enhances the promoter activity. Furthermore, AML1 can synergize or collaborate with C/EBPa and PU.1 in the activation of M-CSF receptor promoter Petrovick et al., 1998) . AML1-ETO does induce the M-CSF receptor activity by itself to a lower level than AML1. However, AML1-ETO enhances AML1 transactivation in a dosage-dependent manner . Further, increased AML1-ETO expression to the level higher than AML1 expression reduces AML1 transactivation. Such effect of AML1-ETO requires minimally the N-terminal portion of ETO, including both NHR1 and NHR2 domains . The promoter of the Bcl-2 gene can also be positively regulated via a consensus AML1 binding DNA sequence by AML1-ETO in transient transfection assays, while AML1 has no effect on the reporter activity (Klampfer et al., 1996) . Both RHD and Cterminal region of AML1-ETO, including NHR4 domain, are critical for the transactivation. In addition, the G-CSF receptor promoter is activated by AML1-ETO. The C-terminal deletion studies reveal that the Nterminal portion of AML1-ETO, including the NHR2 domain, is necessary for the transactivation and the C-terminal 200 a.a.'s are dispensable for this effect (Shimizu et al., 2000) . Interestingly, such activation is independent of the AML1 binding site but is dependent on the C/EBP binding site in the upstream region of the G-CSF receptor gene. Further analysis demonstrate that C/EBPe expression is increased by AML1-ETO and C/EBPe activates the G-CSF receptor promoter via the C/EBP binding site (Shimizu et al., 2000) . The precise mechanism by which AML1-ETO induces C/EBPe expression is still not understood. These observations suggest that AML1-ETO is not just a negative regulator of AML1 targets, but that it also functions as a transactivator of specific genes that contain AML1 binding sites. It is not clear whether ETO interacts with any positive regulators, such as coactivators p300 or CBP, in the activation of gene expression.
On the other hand, AML1-ETO also binds to other transcription regulators via its RHD or ETO portion and can regulate gene expression independent of any AML1 binding site. The RHD interacts with C/EBPa, PU.1, and MEF. AML1-ETO has been reported to regulate negatively the transcriptional activity of these factors. AML1-ETO competes with c-Jun in binding to PU.1 and blocks the coactivator activity of c-Jun (Vangala et al., 2002) . It can also repress C/EBPadependent transcription through an adjacent AML1 binding site (Westendorf et al., 1998) or blocks C/EBPapositive autoregulatory regulation of the C/EBPa own promoter . The association with MEF promotes the inhibition of MEF-induced transcription, independent of AML1-ETO binding to DNA (Mao et al., 1999) . Furthermore, AML1-ETO interacts with PLZF and Gfi proteins via its ETO portion. PLZF is itself involved in myeloid leukemia in t(11;17) and functions as a repressive transcription factor blocking myeloid cell growth and differentiation and promoting apoptosis (Shaknovich et al., 1998) . The region of AML1-ETO between NHR1 and NHR2 is required for the interaction with PLZF (Melnick et al., 2000b) . ETO behaves as a corepressor of PLZF in the inhibition of promoter activity of IL-3 receptor via a PLZF DNA binding site. The interaction of NCoR/SMRT with the NHR4 zinc-finger domain plays a critical role in this corepressor activity (Melnick et al., 2000b) . However, AML1-ETO inhibits the repressor activity of PLZF (Melnick et al., 2000a) . AML1-ETO reduces PLZF DNA binding and also disrupts the nuclear matrix compartmentalization of PLZF. Such effects of AML1-ETO are also dependent on its zinc-finger NHR4 domain (Melnick et al., 2000a) . These are very interesting reports showing the opposite effect of AML1-ETO and ETO on the regulation of gene expression. Protooncogene products Gfi-1 and Gfi-1b are related zincfinger DNA binding transcription repressors and are highly expressed in hematopoietic cells (Gilks et al., 1993; Tong et al., 1998) . They are essential factors for normal hematopoiesis (Karsunky et al., 2002; Saleque et al., 2002; Hock et al., 2003) . It has been recently reported that ETO binds to Gfi-1 and Gfi-1b via its NHR1 and NHR2 domains and facilitates the recruitment of the HDAC complex to the repressor activity of these Gfi-1 proteins (McGhee et al., 2003) . Whether and how AML1-ETO may affect Gfi-1 function has not been clarified yet. However, as described in more detail in the next section, expressing AML1-ETO in K562 and MEL cells and in primary erythroid progenitors block erythroid differentiation (Le et al., 1998; Harada et al., 2001; Tonks et al., 2002) . The possible interaction between Gfi-1 and AML1-ETO may contribute to the disruption of the normal function of Gfi-1. Taken together, these reports about AML1-ETO in the regulation of gene expression indicate that AML1-ETO may function as a transcription repressor or activator. Its function may depend on the AML1 DNA binding site in the regulatory element of its target gene or may be through its interaction with other transcription regulators. Therefore, such effect may be related to the presence of other factors in specific cells, the specific differentiation stage, or particular cellular condition. Additional studies related to the molecular mechanism of AML1-ETO function in the regulation of gene expression will provide further insight into the role of AML1-ETO during leukemogenesis.
AML1-ETO in cell proliferation, differentiation, and survival
The disruption of normal cell proliferation, differentiation, and survival contribute to the development of leukemia. To understand the mechanism of how t(8;21) fusion protein is involved in leukemogenesis, many groups have studied the effect of AML1-ETO on cellular behavior using either hematopoietic cell lines or primary human or mouse bone marrow cells. In various stably transfected AML1-ETO-expressing hematopoietic cell lines, including 32D, L-G, K562, MEL, and U937 cells, AML1-ETO is shown to block myeloid and erythroid differentiation (Ahn et al., 1998; Kitabayashi et al., 1998; Le et al., 1998; Hwang et al., 1999; Kohzaki et al., 1999; Shimizu et al., 2000; Amann et al., 2001; Burel et al., 2001; Harada et al., 2001) . In 32D and L-G cells, AML1-ETO blocks their differentiation and promotes G-CSF-dependent proliferation (Ahn et al., 1998; Kitabayashi et al., 1998; Kohzaki et al., 1999) , which is accompanied by the upregulation of the G-CSF receptor expression by increased C/EBPe. (Shimizu et al., 2000) . In U937 cells, however, the block of differentiation is accompanied by a decreased C/ EBPa expression Pabst et al., 2001) . Furthermore, using stably transfected inducible AML1-ETO-expressing cell lines, AML1-ETO showed a negative effect on cell cycle and survival, including a G1 arrest associated with decreased CDK4 and c-Myc expression (Amann et al., 2001; Burel et al., 2001) . More recently, it was shown that treating inducible AML1-ETO-expressing U937 cells with an inhibitor of c-Jun Nterminal kinase (JNK) or coexpression of the JNK inhibitor protein 1 significantly reduced AML1-ETO promoted apoptosis (Elsasser et al., 2003) . These observations demonstrate that AML1-ETO has an effect on the cellular programs related to proliferation, differentiation, and apoptosis.
In retrovirally transduced primary human CD34 þ cells, AML1-ETO promoted self-renewal following an initial block in colony formation and proliferation in methylcellulose and liquid cultures, respectively (Mulloy et al., 2002) . A similar approach showed that differentiation of CD34 þ /CD13 À erythroid cells were abrogated in the presence of AML1-ETO (Tonks et al., 2002) . Erythroid progenitors with AML1-ETO expression produced fewer number and smaller erythroid colonies in colony-forming assays. According to the authors (Tonks et al., 2002) , erythropoiesis can be distinguished into two stages. The early stage is independent of EPO and the late stage is dependent on EPO. AML1-ETO expression inhibits EPO-independent proliferation of these cells and slows down the G1 to S phase transition of the cell cycle. It also blocks the growth arrest at the boundary of EPO-independent to EPO-dependent stage of erythropoiesis and results in the expansion of erythroid progenitors (Tonks et al., 2002) . It is difficult to separate the promotion of self-renewal from the inhibition of differentiation. The disruption of cell differentiation will keep the proliferation potential of early progenitor cells and promote their expansion. Conceivably, the additional mutations that enhance the cell proliferation will result in the uncontrolled expansion of early progenitors, which initiates leukemogenesis. A more recent report indicates that retroviral-mediated AML1-ETO-expressing human CD34 þ cells, after a long-term in vitro culture, can still differentiate into myeloid and lymphoid lineages, and that most importantly they do not promote leukemia in NOD/SCID mice (Mulloy et al., 2003) . A similar effect of AML1-ETO on growth and differentiation is observed in the in vitro assays of primary mouse bone marrow progenitor cells (Okuda et al., 1998; Hug et al., 2002) . Furthermore, the loss of the NHR2 and NHR4 domains together eliminates such effect of AML1-ETO fusion protein (Hug et al., 2002) . Taken together, these observations suggest that AML1-ETO could exert its oncogenic potential by mechanisms of blocking differentiation and promoting the selfrenewal of stem cells and early progenitors. The ETO portion is critical for such effects. Furthermore, the acquisition of secondary events that disrupt the inhibition of cell cycle by AML1-ETO is necessary for leukemia development. Such potential is well supported by in vivo studies using animal models, which go beyond the scope of this review (Yergeau et al., 1997; Okuda et al., 1998; Yuan et al., 2001; de Guzman et al., 2002; Higuchi et al., 2002; Schwieger et al., 2002; Grisolano et al., 2003) .
Microarray analysis to study the effect of AML1-ETO expression on gene regulation is a powerful technology used to elucidate the molecular mechanism of AML1-ETO in leukemogenesis. One such approach using murine L-G granulocytic progenitor cells showed that the presence of AML1-ETO promotes the differentiation of these cells to a promyelocyte stage based on the induction of various genes involved in azurophil granule formation at this early stage of differentiation (Shimada et al., 2002) . This finding corroborates the observed phenotype of t(8;21) patient samples that display such granules in their cytoplasm. A more recent study using U937 cells with inducible AML1-ETO expression and microarray analysis reveal that the expression of various genes are disrupted or enhanced upon the induction of AML1-ETO (Alcalay et al., 2003) . Examples of disrupted targets are C/EBPa and b, which are involved in hematopoiesis (Chen et al., 1997; Zhang et al., 1997) . Some examples of induced genes are LMO1 and BCL11A, which have been implicated in lymphoid/myeloid malignancies (Aplan et al., 1997; Liu et al., 2003) . Furthermore, using a differential display approach, Shimada et al. (2000) has reported that AML1-ETO activate the expression of TIS11b (also called ERF-1 or cMG1) gene. Over expression of TIS11b in L-G cells increases cell proliferation and delays cell differentiation in response to G-CSF treatment, but shows a slight reduction in cell proliferation in the presence of IL-3 (Shimada et al., 2000) . An interesting recent finding is that AML1-ETO in the inducible U937 cell line disrupts the expression of some genes involved in DNA repair, such as FEN1, OGG1, POLD2, and POLD3 (Alcalay et al., 2003) . The null mutants of these factors have all been suggested to play a role in rapid tumor progression and/or cancer susceptibility. Their dysregulated expression could contribute to genetic instability at the onset of acquiring AML1-ETO and cause the accumulation of DNA mutations involved in the progression of AML-M2 phenotype, which is determined by the combinatory effect of the mutations and the presence of AML1-ETO. These observations are further in support of a 'secondary mutagenic event(s)' model proposed for AML1-ETO leukemogenesis (Yuan et al., 2001; Higuchi et al., 2002; Schwieger et al., 2002; Grisolano et al., 2003) . Thus, finding the crucial pathways required for AML1-ETO to fully transform a myeloid cell to leukemia remains the great challenge.
Summary
The t(8;21) fusion protein AML1-ETO is a multifunctional protein exemplified by its role in regulating diverse cellular programs such as differentiation, proliferation, apoptosis, and self-renewal in various in vitro and in vivo models. It regulates the expression of both AML1 target and non-AML1 target genes via its interaction with various transcription regulators. Furthermore, additional mutations besides t(8;21) are necessary for the development of AML. The challenging questions with regard to t(8;21) involved leukemogenesis remain as: what are the critical target genes regulated by AML1-ETO and what are the molecular pathways that cooperate with AML1-ETO in promoting the oncogenesis of hematopoietic cells? The massive amount of new information about the human and mouse genomes and new technology development will greatly enhance our ability to address these interesting questions.
